This project aims to evaluate the potential rapid and sustained antisuicidal and antidepressant effects of a single intranasal dose of ketamine in inpatients during a mood episode in Major Depressive Disorder (MDD) or Bipolar Disorder (BD) with or without comorbid recent abuse of alcohol.
Country United States of America
Visit trial
Status
Recruiting
Results Published
No
Start date
01 May 2008
End date
25 December 2022
Phase
Phase III
Design
Blinded
Type
Interventional
Generation
First
Participants
50
Sex
All
Age
21- 60
Therapy
No
Trial Details
Clinicians have a limited ability to predict imminent suicidal behaviour and efficacious treatments are not available to treat suicidal patients. Thus, Rapid-acting treatments for suicidal individuals are truly needed. This project aims to evaluate the potential rapid and sustained antisuicidal and antidepressant effects of a single intranasal dose of ketamine in inpatients during a mood episode (in Major Depressive Disorder, MDD or Bipolar Disorder, BD) with or without comorbid recent abuse of alcohol. These results will elucidate the antisuicidal effects of ketamine using the intranasal route along with the identification of associated mediators or moderators; this approach has the potential for enormous public health impact.Trial Number NCT03539887
Sponsors & Collaborators
University of TexasThe University of Texas is conducting research with psychedelics across locations in Houston, Austin, Dallas and San Antonio.
The University of Texas Health Science Center
This company doesn't have a full profile yet, it is linked to a clinical trial.
Measures Used
Montgomery-Asberg Depression Rating ScaleA ten-item diagnostic questionnaire used to measure the severity of depressive symptoms in patients with mood disorders.